- SPACs
- Orisun Acquisition Corp.
Orisun Acquisition Corp.
Completed 2020-11-17- CIK 1770251
- ORSN
- Now UK
- IPO 2019-08-05
- 76 filings
Successfully merged with Ucommune Group Holdings Limited • Now trading as UK
- IPO Size
- $40M
- raised at the IPO
- Current Status
- Completed
- from its latest filing
- IPO Year
- 2019
- year it listed
Filings, by quarter
76 filings over 8 quarters; violet bars carry a milestone
- 19 Q2: 5 filings
- 19 Q3: 18 filings
- 19 Q4: 4 filings
- 20 Q1: 13 filings
- 20 Q2: 3 filings
- 20 Q3: 9 filings
- 20 Q4: 20 filings
- 21 Q1: 4 filings
- S-1 filed 19 Q2
- IPO 19 Q3
- Definitive agreement 20 Q2
- Completed 20 Q4
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
- Registration2019-04-02 Filed S1
- IPO2019-08-05 IPO, search begins
- Definitive Agreement2020-06-29 Agreement for merger
- Completed2020-11-17 Merger Completed
About
Orisun Acquisition Corp. is a blank-check company seeking to acquire an operating business. It intends to focus on technology/high-tech targets in the United States, but may consider other industries.
Investment Focus
Technology
Geographic Focus
United States
Key Information
As the filings state it
- IPO Date
- 2019-08-05
- PIPE
- $66M
- SIC
- 6770
- Completion Date
- 2020-11-17
- Merger Target
- Ucommune Group Holdings Limited
- SPAC Ticker
- ORSN
- Merged Ticker
- UK
Stock Performance
UKTrading symbol, and its price at each step since the first trade
| Point | Date | Price | Move |
|---|---|---|---|
| First Trade | 2019-11-07 | $9.85 | |
| At Merger | 2020-11-18 | $8.56 | -13% |
| 6 Months Post-Merger | 2021-05-20 | $2.11 | -75% |
| 1 Year Post-Merger | 2021-11-18 | $0.94 | -89% |
| 2 Years Post-Merger | 2022-11-18 | $1.72 | -80% |
| Current Price | 2026-10-09 | $2.02 | -79% |
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
The team includes CEO, Chairman and President Wei Chen, an independent investor with high-technology, health and entertainment experience; CFO and Director Lu Zhou, with project-management and financing experience; and independent directors Lihua Zheng, Ling Wu and Tony Chi Ming Chan, with backgrounds in therapeutics, law, information technology, investment banking and finance.